🔷 Findings from BRIGHT-2 provide important insights into combination therapy approaches for HR+ advanced breast cancer following endocrine progression.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd #BreastCancer #AdvancedBreastCancer #HRPositive #Oncology #CancerResearch
🔷 Development of Giredestrant continues across settings, including evERA in advanced disease (NDA accepted by the FDA) and lidERA in early breast cancer, with submission planned soon.
🔗 Read more: bit.ly/ONCOnews09Ma...
#ONCOnews #OncoAlert #OncEd #BreastCancer #AdvancedBreastCancer #Metastatic
A randomized, double-blind, phase 3 #ClinicalTrial evaluating the efficacy of #Culmerciclib + #Fulvestrant in HR-positive, HER2-negative #AdvancedBreastCancer showed improved progression-free survival & tolerable safety.
#STTT #OpenAccess: doi.org/10.1038/s413...
They now have access to the therapy without financial burden.
🤝🏾 This milestone reflects what’s possible when partners come together to put patients first.
buff.ly/1wJxedM
#AdvancedBreastCancer #BreastCancerTreatment #AccessToCare #GlobalHealth #TheMaxFoundation
Major advances in treatment and care have led to improved survival for many women with advanced breast cancer, new study finds.
youtu.be/nJWKKsdFvYw
#MetastaticBreastCancer #AdvancedBreastCancer #BreastCancerSurvival #HER2Positive #HormoneReceptorPositive #TripleNegativeBreastCancer
🔍Explore the Advanced Breast Cancer Tool in ONCOassist #breastcancerawareness 🎀
A quick, evidence-based aid for treatment decision support in metastatic breast cancer.
#ONCOassist #AdvancedBreastCancer #BreastCancer #ABCTool #OncologyTools #ClinicalCalculator
Join Us Wednesdays in October for the Advanced Breast & Gynecologic Cancer webinar series from 12-1PM, live on Zoom.
Learn more and register for each webinar: bccr.org/advanced-bre...
#Metastatic #AdvancedBreastCancer #AdvancedGynecologicCancer #WebinarSeries
#oncology #Novartis #MHRA #MHRAauthorisation #ribociclib #Breastcancer #Breastcancertherapy #aromataseinhibitor #advancedbreastcancer #MHRAdecision #phaseIIIclinicaltrial #NATALEEclinicaltrial l #overallsurvival #patientoutcomes #NICE #SMC #NHSreimbursement
pharmatimes.com/news/novarti...
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites
oncodaily.com/science/bisp...
#AdvancedBreastCancer #ColorectalCancer #M701 #GastricCancer #LungCancer #OvarianCancer #Antibody #ASCO24 #BispecificAntibody #Catumaxomab #EpCAM #ESMO #Immunotherapy#TargetedOncology